There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dynavax (DVAX) and SAGE Therapeutics (SAGE) with bullish sentiments.
Dynavax (DVAX)
In a report issued on December 3, Matt Phipps from William Blair maintained a Buy rating on Dynavax. The company’s shares closed last Monday at $5.75.
According to TipRanks.com, Phipps ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.2% and a 39.5% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Dynavax has an analyst consensus of Moderate Buy, with a price target consensus of $16.50, which is a 189.0% upside from current levels. In a report issued on December 3, Cowen & Co. also maintained a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
SAGE Therapeutics (SAGE)
William Blair analyst Tim Lugo maintained a Buy rating on SAGE Therapeutics yesterday. The company’s shares closed last Monday at $64.92, close to its 52-week low of $56.50.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 13.2% and a 44.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $107.27 average price target, representing a 69.8% upside. In a report issued on November 20, Stifel Nicolaus also reiterated a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAGE:
